End of Rituximab Maintenance for Low–Tumor Burden Follicular Lymphoma
Mené sur 289 patients atteints d'un lymphome folliculaire, cet essai compare l'efficacité, du point de vue de la durée avant l'échec du traitement, et la toxicité du rituximab en traitement d'entretien par rapport au ritixumab administré à l'observation de la progression de la maladie
Since its approval in 1997, the anti-CD20 monoclonal antibody rituximab has had a profound impact on the treatment and outcome of patients with follicular lymphoma. Overall survival for this incurable disease has dramatically improved over the past two decades, and the routine incorporation of rituximab into chemotherapy regimens has demonstrated significant trends toward improved overall survival compared with chemotherapy alone...